Safe Anticoagulation Management using Point of Care Dr. Tony Avades Sr. Consultant and Head of Chemistry, Endocrinology and POCT Sections DLMP Department.

Slides:



Advertisements
Similar presentations
CAP/POCT 2003 Carol Riley-Hunte, RRT Senior Education Specialist Bayer HealthCare.
Advertisements

What is it? Why do we need it POC?
Activated Clotting Time
What is it? Why do we need it POC?
INR Purpose Monitor the coagulation of blood for those on anti-coagulation therapy Monitor for therapeutic levels of medication Monitor for.
BJH POCT Hemochron Annual Competency
JOURNAL REPORT Hernandez Jay, Hernandez L, Ishimura M, Pascua R.
The Joint Commission Chapter update: Waived Testing
Serving in all areas of the clinical laboratory.
MLAB 2401: C LINICAL C HEMISTRY K ERI B ROPHY -M ARTINEZ Point of Care Testing 1.
IVD and Point of care testing
Quality Control in the Coagulation Laboratory Brisbane Australia Robyn Coleman.
Health Care Facilities  Health care facilities are places that provide care or make it possible for some type of care to be delivered to clients.  Care.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
Bleeding time,clotting time, PT, and PTT
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Week 6: Secondary Hemostasis Plasmatic factors Plasmatic factors Intrinsic pathway Intrinsic pathway Extrinsic pathway Extrinsic pathway Specimen Specimen.
Module 5 Postanalytical Phase of Laboratory Testing.
Hemostasis and Blood Coagulation
MLAB Coagulation Keri Brophy-Martinez
Hypercoagulable States Basic Clinician Training Module 4 Introduction Hypercoagulable States Test Your Knowledge.
WARFARIN AN OVERVIEW.
©2007 Wortham Laboratories, Inc.
The Clinical Guide “A Guide to Implementing Renal Best Practice in Haemodialysis“ Chapter 5: Anticoagulation Team Leader: Angela Henson Co-authors: Franta.
IIIIIIIIIIIIIIIIII Point of care testing (POCT) Dr K.A.C.Wickramaratne.
Neurology APTT, PTT, PT, INR. Neurology APTT, PTT, PT, INR.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
Point of Care testing (POCT) For Sexually Transmitted Infections (STI) Barbara Bewley Operations Manager Pathology Clinical Services.
  The prothrombin time is therefore the time required for the plasma to clot after an excess of thromboplastin and an optimal concentration of calcium.
Transfusion Management of Massive Haemorrhage in Adults Patient bleeding / collapses Ongoing severe bleeding eg: 150 mls/min and Clinical shock Administer.
IN THE NAME OF GOD Quality Assurance and Blood Bank S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO)
 Healthcare management can be defined as the use of clinical and information technology, as well as managerial and leadership skills, to ensure the optimal.
In this exercise, two tests will be performed to screen for defective clotting factors. The formation of thrombin in the plasma samples will be inhibited.
· Lecture 31 & 32 : Scope of clinical biochemistry ط Uses of clinical biochemistry tests ط Diagnosis, Prognosis, Screening, Monitoring ط Reporting results.
Investigation of Haemostasis MS. c. program Lab-9.
To understand blood coagulation tests it is helpful to have a basic understanding of the role of the different blood clotting factors and the coagulation.
Dispensary and Administration Site Information Presentation.
© Copyright, The Joint Commission 2015 National Patient Safety Goals.
Barcode Technology in healthcare Nowadays, published reports illustrate high rates of medical error (adverse events) and the increasing costs of healthcare.
Activated Partial Thromboplastin Time (aPTT)
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
Patient Blood Management Guidelines: Module 6 Neonatal and Paediatrics Roles Senior clinician Coordinate team and allocate roles Determine volume and type.
Haemostasis. Indications for hemostasis test – Identify patients presenting with bleeding that have a correctable bleeding tendency – Identify patients.
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
‘Preventing and treating blood clots’ The South Tees Anticoagulation Team 1.
Course Lecturer: Imon Rahman
CAREERS IN PATHOLOGY. PATHOLOGY Pathology is described as “the study of disease” or in other words the scientific study of the way things go wrong In.
Bleeding Tendency Dr. Mervat Khorshied Ass. Prof. of Clinical and Chemical Pathology.
QUALITY CARE/NPSG’S NUR 152 Week 16. OBJECTIVES Define quality improvement and the methods used in health care to ensure quality care. State understanding.
National Patient Safety Goals (NPSG) Online Orientation -the purpose is to improve patient safety -the goals focus on problems in health care safety and.
Introduction to Quality Assurance. Quality assurance vs. Quality control.
MLAB Coagulation Keri Brophy-Martinez
General Approach of Haemostasis
Paediatric Cardiac Pharmacist Bristol Royal Hospital for Children
General Principles of Hemostasis Kristine Krafts, M.D.
General Approach in Investigation of Hemostasis
2017 National Patient Safety Goals
Point of Care Testing California Clinical Laboratory Association
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Aug, 2016.
Activated Partial Thromboplastin Time (aPTT)
Reversal of Direct Oral Anticoagulants (DOAC)
Hemophilia By: Renee Marie Alta.
Hematology and Coagulation Procedures
Introduction To Medical Technology
General Principles of Hemostasis Kristine Krafts, M.D.
Presentation transcript:

Safe Anticoagulation Management using Point of Care Dr. Tony Avades Sr. Consultant and Head of Chemistry, Endocrinology and POCT Sections DLMP Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Point of Care testing (POCT) Tests that are performed at the bedside..near patient.. physician office = Point of care. All diagnostic tests evolved from Point of care Example is urine test at the bedside> moved to>>side room>>moved inside the lab Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

POCT Technology New technological innovation is delivering – Improved – Simple – Shorter analysis time – Smaller Devices Laboratory concerns – Non-lab personnel carrying out lab work – Quality Assurance – Encroaching on the lab territory 3 Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Evolution of healthcare and laboratory medicine Future for health care provider and POCT Reversal of Centralization, since centralization can lengthen the diagnostic decision But more economically from the lab standard 4 Home Doctors clinic Hospital

Doctor ↔ PatientPrepare request formPhlebotomySample transportRegister samplePrepare sampleAnalyze sampleQuality controlValidate result Report resultTransmit resultRecord result in EMR 5

POCT tests designed to be used at or near the site where the patient is located, that do not require permanent dedicated space, are performed outside the physical facilities of the clinical laboratories and that is performed by non-laboratory personnel. College of American Pathologists (CAP) Point of Care Testing Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

POCT HMC Policy 7211 The policy is formulated for all Hamad Medical Corporation services and staff for the establishment of a safe and functional POCT program. It is for all laboratory tests approved by the POCT Coordinating and Steering Committee.

The availability of the result within minutes of asking the clinical question improves the outcome BUT have to ensure safety and quality Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Risk is the chance of suffering harm / error and it can be estimated from the probability of the event and the severity of the harm. Safe POCT is achieved by application of the approved policy, procedures and practices to the task of analysing, evaluation, controlling and monitoring risk. Risk management of POCT activities is by validating the tests before use, trouble shooting of failed QC, performing maintenance, ensuring operators are trained, inventory control. Defining Risk for POCT

Main risks of POCT Unqualified lab users-Nurses – Have minimum lab skills perform POCT testing – They are focused on patient care Quality Control – A liquid sample of known concentration – Preferably two levels are used to prove stability of the testing. – It detects systemic error not random error Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Role of POCT co-ordiator Training Competency assessment Quality control, internal and external Writing and reviewing the Operating procedures Devices and inventory control Ensuring Results are – reported with an appropriate reference ranges – documented with patient record which are accessible by all care giver Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Anti Coagulation POCT PT/INR ACT TEG Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Why do we need anticoagulant study? Clotting is associated with disease conditions  Artificial heart valve replacement  Myocardial Ischaemia  Atrial fibrillation (AF)  Deep Vein Thrombosis (DVT)  Pulmonary embolus  Hereditary disorders ~ deficiencies in blood proteins or production of antibodies that cause the blood to clot or prevent the blood from clotting Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

PT = Prothrombin Time. It is a measure of how quickly blood clots. INR = International Normalized Ratio The ideal target INR range will vary from person to person depending on a variety of factors such as; Reason for taking anticoagulants Medical conditions Other issues. The traditional way to run a PT-INR test is to have blood drawn and sent to a lab, where the test is conducted Why Do We Need PT/INR Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

PT/INR Measure of the extrinsic pathway POCT devices strips containing thromboplastin reagents (variable sources) Fresh whole blood Clot detection – The lab uses either optical or mechanical means – POCT Capillary or pump-induced movement Oscillation change of a magnetic particle Electro-current by alteration of fluorescence Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

HMC POCT PT/INR devices InstrumentManufacturerFresh whole blood Citrated whole blood Citrated plasma Sample size CoagCheckRocheYesNo 10 – 25ul HemochronITCYesNo 25ul Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Roche CoaguChek XS Pro System Components CoaguChek XS Pro Handheld Base Unit* Handheld Battery Pack * Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section 19

Principle The CoaguChek test strip contains recombinant thromboplastin reagent. When the whole blood sample is applied, the reagent is solved and an electrochemical reaction takes place which is transformed into a clotting time value being displayed on the meter screen in INR values. The international sensitivity index (ISI) for the system has been established as 1 Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Hemochron Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Hemochron Signature Elite Components Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section 22

Hemochron Jr. Test Cuvettes Test type is read automatically from the cuvette. CuvetteIntended UseSpecimenReporting Unit ACT-LR Monitors low to moderate heparin doses up to 2.5 units/mL of blood. Used in procedures such as cardiac catherization, Extracorporeal Membrane Oxygenation (ECMO), dialysis and Pertaneous Transluminal Cornary Angioplasty. Whole bloodCelite Equivalent Seconds ACT+ Monitors moderate to high levels of heparin (1- 6 units/mL ). Unaffected by aprotinin upto 500 KIU/mL of blood, hypothermia, and hemodilution. Whole bloodCelite Equivalent Seconds Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

ACT Coagulation initiated by an activator Clot detection is change in pump driven blood movement Strong activator kaolin or celite Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Why use ACT Monitoring hemostatsis for heparin anticoagulant therapy Bleeding clotting Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Rapid TAT Rapidly adjust anticoagulant dose Heparin – half life varies by patient – Dose required varies by patient – Potency varies by lot Direct thrombin inhibitors – very short half life – Require immediate intervention – No antidote available Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

ACT Cardiac surgery Percutaneous coronary intervention (PCI) Interventional cardiology ECMO Critical care Interventional radiology Electrophysiology Vascular surgery Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

ACT Activated clotting time POC Only Low, moderate or high dose heparin System dependent APTT Activated partial thromboplastin time Laboratory Low dose heparin only System dependent upper limit Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Challenges Variation in tests results based on the device used INR corrects for variation, not with ACT End-user knowledge of the pre-analytical variables- Training – Sample type: cap avoid messaging, arterial or venous avoid trauma – Size: – timing of collection-immediately Quality assurances Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

TEG measures viscoelastic properties (viscosity) of whole blood. The clot viscoelasticity depends on – Fibrinogen – Platelets – Coagulation – Fibrinolytic proteins Thromboelastograph (TEG)

TEG TEG- abnormal hemostasis and fibronolysis Hepatic disease Cardiac Surgery ECMO Assessment of bleeding peri-operatively and following trauma Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section

Viscoelastometric POC MAY be useful to help determine if bleeding is because of a problem with the blood’s ability to clot, or because of a surgical bleed. This helps the right treatment to stop the bleeding. Using these systems MAY mean that patients are less likely to need a blood transfusion during surgery or need more operations to investigate further bleeding. TEG is recommended to help monitor blood clotting during and after heart surgery by healthcare professionals who have had appropriate training NICE August 2014 Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section TEG and NICE guidelines

THANK YOU Department of Laboratory Medicine & Pathology Point of Care Testing (POCT) Section